Market News / Story
Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for top…
MFN by Modular Finance ·
MFN by Modular Finance reports: Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides an update on the global Phase IIb EPIMODE trial evaluating lead drug candidate CS1 in pulmonary arterial hypertension (PAH). Up to 15 clinical sites are expected to be activated by year-end 2026 as the global trial continues to expand across North America, Europe and…